Characteristics of in study patients stratified by method of nodal sampling
| Characteristic | LND cohort* | SLN cohort* | P value† |
| (n=251) | (n=127) | ||
| Characteristics at the time of surgery | |||
| Age (years) (mean (SD)) | 64.2 (9.1) | 64.1 (9.4) | 0.98 |
| BMI (kg/m2) (median (IQR)) | 32.2 (27.1–37.7) | 33.4 (28.6–40.0) | 0.05 |
| BMI (kg/m2) (n (%)) | 0.049 | ||
| <25.0 | 39/249 (15.7) | 10 (7.9) | |
| 25.0–29.9 | 57/249 (22.9) | 33 (26.0) | |
| 30.0–39.9 | 112/249 (45.0) | 52 (40.9) | |
| 40.0 or higher | 41/249 (16.5) | 32 (25.2) | |
| Comorbidities (n (%)) | |||
| Diabetes | 41 (16.3) | 18 (14.2) | 0.58 |
| CHF | 2 (0.8) | 6 (4.7) | 0.02 |
| Moderate/severe renal disease | 3 (1.2) | 2 (1.6) | 0.99 |
| Surgical details | |||
| FIGO grade (n (%)) | <0.001 | ||
| 1 or 2 (low) | 171 (68.1) | 101 (79.5) | |
| 3 (high) | 80 (31.9) | 26 (20.5) | |
| FIGO stage (n (%)) | 0.28 | ||
| I/II | 227 (90.4) | 119 (93.7) | |
| III/IV | 24 (9.6) | 8 (6.3) | |
| Histology (n (%))‡ | 0.35 | ||
| Non-endometrioid | 43 (17.1) | 17 (13.4) | |
| Endometrioid | 208 (82.9) | 110 (86.6) | |
| Total nodes removed via SLN among those with nodes removed (median (IQR)) | 2 (2–3) | 3 (2–5) | <0.001 |
| LND performed (n (%)) | -- | ||
| No | – | 107 (84.3) | |
| Pelvic only | 147 (58.6) | 15 (11.8) | |
| Para-aortic only | – | 3 (2.4) | |
| Pelvic and para-aortic | 104 (41.4) | 2 (1.6) | |
| Total nodes removed via LND among those with nodes removed (median (IQR)) | |||
| Total pelvic and para-aortic | 31 (23–41) | 7 (5–10) | <0.001 |
| Total pelvic | 25 (19–34) | 7 (6–9) | <0.001 |
| Total para-aortic | 13 (9–19) | 4 (3–5) | <0.001 |
| Total nodes removed by any means (SLN +LND) (median (IQR)) | 31 (24–41) | 4 (3–6) | <0.001 |
| Adjuvant EBRT (n (%)) | 0.58 | ||
| No | 227 (90.4) | 118 (92.9) | |
| Yes | 14 (5.6) | 4 (3.1) | |
| Unknown | 10 (4.0) | 5 (3.9) |
*The LND cohort consisted of patients who underwent bilateral LND prior to SLN implementation at our institution or as 'backup' after SLN mapping, and the SLN cohort consisted of patients who underwent SLN biopsy with or without side specific LND.
†Two sample t test p value presented for age, Wilcoxon rank sum test p values presented for all other continuous variables, and the χ2 or Fisher’s exact test p values presented for categorical variables.
‡Endometrioid histology included endometrioid and mixed endometrioid and mucinous histology; non-endometrioid histology included serous, clear cell, carcinosarcoma, mixed serous, and mixed clear cell histology.
BMI, body mass index; CHF, congestive heart failure; EBRT, external beam radiation therapy; FIGO, International Federation of Gynecology and Obstetrics; LND, lymphadenectomy; SLN, sentinel lymph node.